Clovibactin
Gram-positive bacterial infections (e.g., Staphylococcus aureus, Streptococcus pneumoniae)
Key Facts
About NovoBiotic Pharmaceuticals
NovoBiotic Pharmaceuticals is a pioneering biotech company that has overcome a major bottleneck in natural product discovery by developing innovative culturing technologies, such as the iChip and diffusion chambers, to access the >99% of environmental microbes previously deemed unculturable. This platform has yielded a proprietary library of over 75,000 microbial isolates and led to the discovery of promising new antibiotic classes, most notably teixobactin and clovibactin, which are in late preclinical development. The company is strategically positioned to address the critical global need for novel antibiotics against multidrug-resistant pathogens, operating as a private, grant-funded entity with a lean team focused on advancing its pipeline.
View full company profile